This study evaluates whether addition of Peginterferon alfa-2a to CHB Patients Treated with
nucleoside analogues (NAs) can enhance the rate of HBsAg clearance at end of treatment. This
study is a Randomized, open-label, multi-center study.
The CHB patients with NAs treatment and have achieved HBV DNA <15 IU/ml、HBeAg <100
PEIU/ml、HBsAg positive and HBsAg<1500 IU/ml will be randomized into 2 groups:
Group 1 (Combination group): Maintain NAs treatment while add 48-week standard treatment by
Peginterferon alfa 2a 180µg/week Group 2 (Mono NA group) : Maintain NAs treatment for 49
weeks. Note: NAs including: LAM, ADV, ETV, or TDF.